All In Biotech

Drug Trial Radar · NCT07173855

Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients

Effect of Protocolized Magnesium Replacement in Critically Ill Patients on Mortality and Atrial Fibrillation: the MAGNOLIA Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,853 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,853

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Mar 1, 2027

Study completion Jun 1, 2027

Sponsor

Lead sponsor
Scarborough General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Scarborough Health Network; Lakeridge Health Corporation
First posted
Sep 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The main question this study aims to answer is whether magnesium supplementation protocols targeting a higher or lower level lead to better 30-day survival and less atrial fibrillation. Participants will not have to do any specific tasks, undergo any additional tests, or complete any surveys.

Conditions

  • Critical Illness

Interventions

  • Magnesium sulfate administrationDrug

    Magnesium sulfate is used in both arms for magnesium replacement.

  • Magnesium oxideDrug

    In the higher-target arm, magnesium oxide 420mg po q12h x 2 is one of the options available for magnesium replacement when magnesium levels lie between 0.75 and 0.95mmol/L.

  • Magnesium glucoheptonateDrug

    Magnesium glucoheptonate 30mL po q12h x 2 is an oral option for magnesium replacement in the higher-target arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30-day ordinal composite of hospital mortality and days free of atrial fibrillation in ICUTime frame: 30 days after enrollment.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Lakeridge Health Ajax-Pickering

    Ajax, Ontario, Canada · Recruiting

  • Lakeridge Health Bowmanville

    Bowmanville, Ontario, Canada · Recruiting

  • Lakeridge Health Oshawa

    Oshawa, Ontario, Canada · Recruiting

  • Scarborough Centenary Hospital

    Toronto, Ontario, Canada · Recruiting

  • Scarborough General Hospital

    Toronto, Ontario, Canada · Recruiting

  • Scarborough Birchmount Hospital

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.